Vertex Pharmaceuticals (VRTX) Current Deferred Revenue (2009 - 2017)

Vertex Pharmaceuticals has reported Current Deferred Revenue for 9 years, with the latest figure at $5.2 million in Q4 2017.

• On a quarterly basis, Current Deferred Revenue fell 13.92% year-over-year to $5.2 million in Q4 2017; TTM through Dec 2017 was $5.2 million, a 13.92% decrease from a year earlier, with the FY2017 full-year figure at $5.2 million, down 13.92% from the prior year.
• Current Deferred Revenue was $5.2 million for Q4 2017 at Vertex Pharmaceuticals, down from $13.0 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $35.5 million in Q1 2013, with the low at $5.2 million in Q4 2017.
• Average Current Deferred Revenue over 5 years is $17.5 million, with a median of $15.4 million recorded in 2015.
• The sharpest annual moves came in 2016 and 2017: Current Deferred Revenue sank 63.15% in 2016, then surged 40.62% in 2017.
• Over 5 years, Current Deferred Revenue stood at $21.5 million in 2013, then declined by 18.79% to $17.5 million in 2014, then dropped by 6.71% to $16.3 million in 2015, then tumbled by 63.15% to $6.0 million in 2016, then slipped by 13.92% to $5.2 million in 2017.
• The last three Current Deferred Revenue figures came in at $5.2 million (Q4 2017), $13.0 million (Q3 2017), and $7.3 million (Q2 2017), per Business Quant data.